Determinants of public expenditures for medicinal products in non hospital consumption in Slovenia

Simple item page
dc.contributor.authorKajdiž, Romana
dc.contributor.authorBojnec, Štefan
dc.contributor.otherEkonomická fakultacs
dc.date.accessioned2014-08-28
dc.date.available2014-08-28
dc.date.defense2014-09-04
dc.description.abstractThe Slovenian government aims to regulate prices for medicinal products to manage and reduce public expenditures for medicinal products. This paper aims to investigate the association between the regulated wholesale prices of medicinal products and the public expenditures for medicinal products, and to estimate regression model for public expenditures for medicinal products in the non hospital consumption. In the empirical research are included 758 regulated prices for medicinal products prescribed by the outpatients’ department on a prescription (Rp) during the years 2003–2010, which are financed from public expenditures. The correlation and regression analyses are used in order to establish the association between the regulated wholesale prices for medicinal products and the public expenditures for medicinal products. The correlation analysis confirmed a strong positive correlation of the public expenditures for medicinal products with the number of Rp or the number of boxes on the Rp prescription, a weak correlation with the wholesale prices for medicinal products and with the classification lists of medicinal products. The multiple regression analysis confirmed a positive significant impact of the wholesale price of medicinal products and the number of Rp or the number of boxes on the Rp prescription, on the public expenditures for medicinal products. The research has confirmed the association of the public expenditures for medicinal products with the regulated wholesale prices for medicinal products. It has underlined the importance of the rational prescription and use of medicinal products. The explanatory variables included in the regression model for the public expenditures for medicinal products explained up to 94% of variability in the public expenditures for medicinal products.en
dc.formattext
dc.format.extent27-34 s.cs
dc.identifier.doi10.15240/tul/001/2014-3-003
dc.identifier.eissn2336-5604
dc.identifier.issn12123609
dc.identifier.urihttps://dspace.tul.cz/handle/15240/7084
dc.language.isoen
dc.publisherTechnická Univerzita v Libercics
dc.publisherTechnical university of Liberec, Czech Republicen
dc.publisher.abbreviationTUL
dc.relation.isbasedonARTS, D., HABL, C. ROSIAN, I., VOGLER, S. Pharmaceutical pricing and reimbursement information (PPPI): a European Union project. Italian Journal of Public Health. 2006, Vol. 3, Iss. 1, pp. 213-234. ISSN 1723-7815.
dc.relation.isbasedonČEPAR, Ž. Visokošolsko izobraževanje v Sloveniji: analiza povpraševanja. Koper: Založba Univerze na Primorskem, 2010. ISBN 978-961-6832-01-4.
dc.relation.isbasedonDICKSON, M., REDWOOD, H. Pharmaceutical reference prices: How do they work in practice? Pharmacoeconomics. 1998, Vol. 14, Iss. 5, pp. 471-479. ISSN 1170-7690.
dc.relation.isbasedonESPIN, J., ROVIRA, J. External Price Referencing. WHO/HAI project on medicines prices and availability. Policy paper, 2010.
dc.relation.isbasedonFÜRST, J., SAMALUK, V. Predpisovanje zdravil v letu 2006. Zdravstveni Vestnik. 2007, Vol. 76, pp. 487-489. ISSN 0350-0063.
dc.relation.isbasedonGIULIANI, G., SELKE, G., GARATTINI, L. The German experience in reference pricing. Health Policy. 1998, Vol. 44, Iss. 1, pp. 73-85. ISSN 0168-8510.
dc.relation.isbasedonIYN-HYANG, L., BLOORB, K., HEWITTB, C., MAYNARDB, A. The effects of new pricing and copayment schemes for pharmaceuticals in South Korea. Health Policy. 2012, Vol. 104, Iss. 1, pp. 40-49. ISSN 0168-8510.
dc.relation.isbasedonJÁNOŠÍKOVÁ, L. Reduction of a hospital network as a multiple criteria optimisation problem. E+M Ekonomie a Management. 2009, Vol. 12, Iss. 3, pp. 50-57. ISSN 1212-3609.
dc.relation.isbasedonKAJDIŽ, R., BOJNEC, Š. Ali regulacija in kritje cen zdravil vplivata na javne izdatke za zdravila? Zdravniški vestnik. 2012, Vol. 81, No. 9, pp. 618-625, ISSN 1581-0224.
dc.relation.isbasedonKAJDIŽ, R., BOJNEC, Š. Učinki sistema referenčnih cen na oblikovanje cen zdravil. Management. 2010, Vol. 5, Iss. 1, pp. 53-67. ISSN 1854-4231.
dc.relation.isbasedonLEOPOLD, C., VOGLER, S., MANTEL-TEEUWISSE, A.K., DE JONCHEERE, K., LEUFKENS, H.G.M., LAING, R. Differences in external price referencing in Europe – A descriptive overview. Health Policy. 2012, Vol. 104, Iss. 1, pp. 50-60. ISSN 0168-8510.
dc.relation.isbasedonMORENO-TORRES, I., PUIG-JUNOY, J., RAYA, J.M. The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain. European Journal of Health Economics. 2010, Vol. 12, Iss. 6, pp. 563-573. ISSN 1618-7598.
dc.relation.isbasedonNEMEC, J., MERIČKOVÁ, B., ŠTRANGFELDOVÁ, J. The ownership form of hospitals from the viewpoints of economic theory and Slovak practice. E+M Ekonomie a Management. 2010, Vol. 13, Iss. 2, pp. 19-31. ISSN 1212-3609.
dc.relation.isbasedonOECD. Health at a Glance: Europe 2010, OECD publishing. Paris: Organisation for Economic Cooperation and Development, 2010. 130 p. Available also from: http://dx.doi.org/10.1787/health_glance-2010-en. ISBN 978-92-64-09031-6.
dc.relation.isbasedonPEČAR-ČAD, S., HRIBOVŠEK, T. Ambulantno predpisovanje zdravil v Sloveniji po ATC klasifikaciji v letu 2010. Ljubljana: Inštitut za varovanje zdravja Republike Slovenije, 2011.
dc.relation.isbasedonSCIFF, G.D., GALANTER, W.L. Promoting more conservative prescribing. JAMA. 2009, Vol. 301, Iss. 89, pp. 865-867. ISSN 1538-3598.
dc.relation.isbasedonPARK, S.E., LIM, S.H., CHOI, H.W., LEE, S.M., KIM, D.W., YIM, E.Y., KIM, K.H., YI, S.Y. Evaluation on the first 2 years of the positive list system in South Korea. Health Policy. 2012, Vol. 104, Iss. 1, pp. 32-39. ISSN 0168-8510.
dc.relation.isbasedonVOGLER S, et al. Pharmaceutical Pricing and Reimbursement Information (PPRI): final report. Luxembourg: DG Health and Consumer Protection of the European Commission; 2007. Available also from: http://ppri.goeg.at.
dc.relation.ispartofEkonomie a Managementcs
dc.relation.ispartofEconomics and Managementen
dc.relation.isrefereedtrue
dc.rightsCC BY-NC
dc.subjectdimensions of organizational cultureen
dc.subjectmanagersen
dc.subjectorganizationen
dc.subject.classificationH51
dc.titleDeterminants of public expenditures for medicinal products in non hospital consumption in Sloveniaen
dc.typeArticleen
local.accessopen
local.citation.epage34
local.citation.spage27
local.facultyFaculty of Economics
local.fulltextyes
local.relation.abbreviationE&Men
local.relation.abbreviationE+Mcs
local.relation.issue3
local.relation.volume17
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
EM_03_14_3.pdf
Size:
229.9 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Číslo 3